Patents by Inventor Matthew J. Frigault

Matthew J. Frigault has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTS
    Publication number: 20240133871
    Abstract: The present invention provides novel processes, compositions, and methods for analyzing or assaying the potency and/or functionality of tumor infiltrating lymphocyte (TIL) products for use in therapy, including human cancer therapy, and analyzing or assaying the potency and/or functionality of other polyclonal products, such as marrow infiltrating lymphocyte (MIL) and peripheral blood lymphocyte (PBL) products. Compositions, methods, and kits for preparing and treating cancer using TIL, MIL, and PBL products are also provided.
    Type: Application
    Filed: September 26, 2023
    Publication date: April 25, 2024
    Inventors: Michelle R. Simpson-Abelson, Matthew J. Frigault, Wayne P. Rothbaum, Michael Weiser
  • METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTS
    Publication number: 20240082375
    Abstract: The present invention provides novel processes, compositions, and methods for analyzing or assaying the potency and/or functionality of tumor infiltrating lymphocyte (TIL) products for use in therapy, including human cancer therapy, and analyzing or assaying the potency and/or functionality of other polyclonal products, such as marrow infiltrating lymphocyte (MIL) and peripheral blood lymphocyte (PBL) products. Compositions, methods, and kits for preparing and treating cancer using TIL, MIL, and PBL products are also provided.
    Type: Application
    Filed: September 29, 2023
    Publication date: March 14, 2024
    Inventors: Michelle R. Simpson-Abelson, Matthew J. Frigault, Wayne P. Rothbaum, Michael Weiser
  • METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTS
    Publication number: 20220313806
    Abstract: The present invention provides novel processes, compositions, and methods for analyzing or assaying the potency and/or functionality of tumor infiltrating lymphocyte (TIL) products for use in therapy, including human cancer therapy, and analyzing or assaying the potency and/or functionality of other polyclonal products, such as marrow infiltrating lymphocyte (MIL) and peripheral blood lymphocyte (PBL) products. Compositions, methods, and kits for preparing and treating cancer using TIL, MIL, and PBL products are also provided.
    Type: Application
    Filed: March 25, 2022
    Publication date: October 6, 2022
    Inventors: Michelle R. Simpson-Abelson, Matthew J. Frigault, Wayne P. Rothbaum, Michael Weiser
  • Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
    Patent number: 11299536
    Abstract: The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: April 12, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Matthew J. Frigault, Yangbing Zhao, John Scholler, Carl H. June
  • Compositions and Methods for Generating a Persisting Population of T Cells Useful for the Treatment of Cancer
    Publication number: 20220056116
    Abstract: The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.
    Type: Application
    Filed: May 12, 2021
    Publication date: February 24, 2022
    Inventors: Matthew J. Frigault, Yangbing Zhao, John Scholler, Carl H. June
  • Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
    Patent number: 10800840
    Abstract: The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: October 13, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Matthew J. Frigault, Yangbing Zhao, John Scholler, Carl H. June
  • Compositions and Methods for Generating a Persisting Population of T Cells Useful for the Treatment of Cancer
    Publication number: 20190085063
    Abstract: The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.
    Type: Application
    Filed: June 21, 2018
    Publication date: March 21, 2019
    Inventors: Matthew J. Frigault, Yangbing Zhao, John Scholler, Carl H. June
  • Compositions and Methods for Generating a Persisting Population of T Cells Useful for the Treatment of Cancer
    Publication number: 20180371068
    Abstract: The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.
    Type: Application
    Filed: June 21, 2018
    Publication date: December 27, 2018
    Inventors: Matthew J. Frigault, Yangbing Zhao, John Scholler, Carl H. June
  • Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
    Patent number: 10040846
    Abstract: The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: August 7, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Matthew J. Frigault, Yangbing Zhao, John Scholler, Carl H. June
  • Compositions and Methods for Generating a Persisting Population of T Cells Useful for the Treatment of Cancer
    Publication number: 20150024482
    Abstract: The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.
    Type: Application
    Filed: February 22, 2013
    Publication date: January 22, 2015
    Inventors: Matthew J. Frigault, Yangbing Zhao, John Scholler, Carl H. June